领航医药生物科技中期报告 2022-2023

(IncorporatedintheCaymanIslandsandcontinuedinBermudawithlimitedliability)(于开曼群岛注册成立并于百慕大存续之有限公司) (StockCode股份代号：399) INTERIMREPORT 中期报告 2022/23 Contents 目录 2CorporateInformation 公司资料 4Chairman’sStatement 主席报告 6ManagementDiscussionandAnalysis 管理层讨论及分析 12OtherInformationProvidedinAccordancewiththeListingRules 根据上市规则披露之其他资料 18CondensedConsolidatedStatementofProfitorLossandOtherComprehensiveIncome 简明综合损益及其他全面收益表 21CondensedConsolidatedStatementofFinancialPosition 简明综合财务状况表 24CondensedConsolidatedStatementofChangesinEquity 简明综合权益变动表 26CondensedConsolidatedStatementofCashFlows 简明综合现金流量表 27NotestotheCondensedConsolidatedFinancialStatements 简明综合财务报表附注 CorporateInformation 公司资料 BOARDOFDIRECTORS ExecutiveDirectors GaoYuanXingTangRong Non-executiveDirectors JiangNian(Chairman) XiaoYanWuYanmin Independentnon-executiveDirectors ChenWeijunWangRongliangChenJinzhong AuditCommitteeChenWeijun(Chairman)WangRongliang ChenJinzhong RemunerationCommitteeWangRongliang(Chairman)JiangNian ChenJinzhong NominationCommittee JiangNian(Chairman)WangRongliangChenJinzhong HONORARYCHAIRMAN MaoYumin COMPANYSECRETARY PoonHonYin REGISTEREDOFFICE ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda 董事会 执行董事 高源兴唐榕 非执行董事蒋年（主席）肖焱 邬燕敏 独立非执行董事 陈伟君王荣梁陈金中 审核委员会陈伟君（主席）王荣梁 陈金中 薪酬委员会王荣梁（主席）蒋年 陈金中 提名委员会蒋年（主席）王荣梁 陈金中 名誉主席 毛裕民 公司秘书 潘汉彦 注册办事处ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda 2INNOVATIVEPHARMACEUTICALBIOTECHLIMITED2022/23InterimReport CorporateInformation 公司资料 PRINCIPALPLACEOFBUSINESSINHONGKONG UnitNo.2111,21/F. WestTowerShunTakCentre168–200ConnaughtRoadCentralSheungWan,HongKong PRINCIPALSHAREREGISTRARANDTRANSFERAGENT ConyersCorporateServices(Bermuda)Limited ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda BRANCHSHAREREGISTRARANDTRANSFERAGENTINHONGKONG TricorTengisLimited 17/F,FarEastFinanceCentre16HarcourtRoad HongKong AUDITORS ElitePartnersCPALimited10/F,8ObservatoryRoadTsimShaTsui,KowloonHongKong PRINCIPALBANKER BankofCommunicationsCo.,Ltd. STOCKCODE 399 COMPANYWEBSITE www.ipb.asiawww.irasia.com/listco/hk/ipb 香港主要营业地点 香港上环 干诺道中168–200号信德中心西座 21楼2111室 股份登记总处及过户代理处 ConyersCorporateServices(Bermuda)Limited ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda 香港股份登记分处及过户代理处 卓佳登捷时有限公司香港 夏悫道16号 远东金融中心17楼 核数师 开元信德会计师事务所有限公司香港 九龙尖沙咀 天文台道8号10楼 主要往来银行 交通银行股份有限公司 股份代号 399 公司网站 www.ipb.asiawww.irasia.com/listco/hk/ipb 2022/23年中期报告领航医药及生物科技有限公司3 Chairman’sStatement 主席报告 DearShareholders, Onbehalfoftheboard(the“Board”)ofdirectors(the“directors”)ofInnovativePharmaceuticalBiotechLimited,(the“Company”,togetherwithitssubsidiaries,the“Group”),IherebypresenttoallshareholdersoftheCompany(the“Shareholders”)theunauditedconsolidatedfinancialresultsoftheGroupforthesixmonthsended30September2022(the“FinancialPeriod”)andthesixmonthsended30September2021(the“PreviousFinancialPeriod”). DuetotheCOVID-19isstillaffectingthebusinessenvironment,theGrouponlyrecordedrevenueofapproximatelyHK$4.1millionfortheFinancialPeriod,adecreaseofapproximately37.6%inrevenuefromapproximatelyHK$6.6millionasrecordedinthePreviousFinancialPeriod. TheCompanyreportedalossforthePeriodamountedtoapproximatelyHK$118.3million,ascomparedwiththeprofitforthePreviousFinancialPeriodamountedtoapproximatelyHK$121.11million.ItisduetotheCompanycompletedthesecondamendmentoftheconvertiblebondwithprincipalamountofHK$715millionissuedbytheCompanyduringthePreviousFinancialPeriod,anamountofapproximatelyHK$250.7millionnon-cashitemwascreditedintotheincomestatement. 各位股东： 本人谨代表领航医药及生物科技有限公司（“本公司”，连同其附属公司统称“本集团”）之董事（“董事”）会（“董事会”）向本公司所有股东（“股东”）提呈本集团截至二零二二年九月三十日止六个月（“本财政期间”）及截至二零二一年九月三十日止六个月（“上一财政期间”）之未经审核综合财务业绩。 由于COVID-19仍然影响着经营环境。本集团于本财政期间之收益仅为约4,100,000港元，较上一财政期间录得之收益约6,600,000港元减少约 37.6%。 本公司于期内录得亏损约118,300,000港元，而上一个财政期间则录得溢利约121,110,000港元。由于本公司于上一个财政期间完成本公司所发行本金额为715,000,000港元的可换股债券第二次修订，约250,700,000港元的非现金项目已计入收益表内。 4INNOVATIVEPHARMACEUTICALBIOTECHLIMITED2022/23InterimReport Chairman’sStatement 主席报告 OUTLOOK TheGroupalsoengagesindevelopmentofatechnologythatwouldallowinsulintobeadministeredorally.Thetechnologyisstillintheresearchanddevelopmentstage.TheGrouphascommencedthepartB,PhaseIIIoftheclinicaltrialinAugust2020whichistypicallyconsideredasthefinalstageofclinicaltrialbeforecommercialization.Currently,about296patientshaveparticipatedintheclinicaltrial.AlthoughtheCOVID-19affectedtheprogressofclinicaltrial,theGroupwilluseitsbestendeavourstocommercialisetheproductbythemidof2024. TheCompanycontinuestoactivelypursueandreviewcooperation,jointventures,andinvestmentswithsuitablepartnersandwillcontinuetofocusonimprovingtheGroup’sattractivenessandprofitabilityasnecessarytoenhanceshareholderreturnsandthesustainablelong-termdevelopmentoftheGroupasawhole. APPRECIATION OnbehalfofallthemembersoftheBoard,IwouldliketotakethisopportunitytoexpressmygratitudetotheShareholdersandbusinesspartnersoftheGroupfortheircontinuedsupportandtrustduringthepastyears,andmymostsincereappreciationtothedirectors,management,andstaffatalllevelsfortheirdedication,hardwork,andcontributionstotheGroup. JiangNian Chairman Shanghai,29November2022 展望 本集团亦致力于开发一种令胰岛素